ArticleBioMed research international2022
Studying the Anticancer Effects of Thymoquinone on Breast Cancer Cells through Natural Killer Cell Activity.
Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Machine Learning-driven Prediction of Cervical Cancer Cell Viability After Treatment With Thymoquinone, Curcumin, and 5-Fluorouracil.Applied biochemistry and biotechnology · 2026Article
- Thymoquinone Enhances Tamoxifen Efficacy Against Triple-Negative Breast Cancer by Targeting EMT Signaling.International journal of breast cancer · 2026Article
- Bee venom and thymoquinone combination inhibits cancer cells by inducing cell cycle arrest and apoptosis.Scientific reports · 2025Article
- Anticancer effects of thymoquinone on prostate cancer cells and natural killer cell activity.Oncology letters · 2025Article
- Herbal Medicine in Breast Cancer Therapy: Mechanisms, Evidence, and Future Perspectives.Current issues in molecular biology · 2025Review
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery.Journal of nanobiotechnology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy is quickly growing and can now be viewed as the "fifth column" of cancer treatment. In addition, cancer immunotherapy has shown promising results with different kinds of cancers and may be used as a complementary therapy with various types of treatments. Thus, "immuno-oncology" is showing astounding advantages. However, one of the main challenges that face this type of therapy is that cancer cells can evade immune system elimination through different mechanisms. Many studies were done to overcome this issue including adding immune stimulants to generate synergistic effects or by genetically modifying NK cells themselves to be stronger and more resistant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.